Media headlines about EXACT Sciences (NASDAQ:EXAS) have been trending very positive recently, according to AlphaOne Sentiment Analysis. The research group, a unit of Accern, identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. EXACT Sciences earned a media sentiment score of 0.73 on AlphaOne’s scale. AlphaOne also gave news headlines about the medical research company an impact score of 79 out of 100, indicating that recent press coverage is likely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s scoring:
- Short Interest in EXACT Sciences Co. (EXAS) Decreases By 0.9% (americanbankingnews.com)
- $36.14 Million in Sales Expected for EXACT Sciences Co. (EXAS) This Quarter (americanbankingnews.com)
- EXACT Sciences Co. (EXAS) to Post Q1 2017 Earnings of ($0.40) Per Share, Leerink Swann Forecasts (americanbankingnews.com)
- EXACT Sciences (EXAS) Given News Impact Rating of 0.59 (americanbankingnews.com)
- EXACT Sciences Co. (EXAS) Now Covered by Analysts at Leerink Swann (americanbankingnews.com)
EXAS has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Tuesday, December 27th. Cowen and Company restated an “outperform” rating and set a $30.00 price target on shares of EXACT Sciences in a research note on Tuesday, April 4th. BTIG Research restated a “buy” rating and set a $22.00 price target on shares of EXACT Sciences in a research note on Sunday, January 8th. Craig Hallum set a $28.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Monday, March 27th. Finally, Canaccord Genuity set a $24.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Monday, January 23rd. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.00.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/exact-sciences-exas-getting-very-positive-news-coverage-analysis-shows/1289395.html
EXACT Sciences (NASDAQ:EXAS) opened at 24.24 on Friday. EXACT Sciences has a 1-year low of $5.36 and a 1-year high of $24.95. The company has a 50-day moving average of $22.25 and a 200-day moving average of $18.46. The stock’s market capitalization is $2.68 billion.
EXACT Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, February 21st. The medical research company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. The company earned $35.24 million during the quarter, compared to analysts’ expectations of $32.53 million. EXACT Sciences had a negative net margin of 216.45% and a negative return on equity of 55.44%. EXACT Sciences’s quarterly revenue was up 144.4% on a year-over-year basis. During the same period last year, the company posted ($0.41) earnings per share. Analysts anticipate that EXACT Sciences will post ($1.47) earnings per share for the current fiscal year.
In other EXACT Sciences news, COO Maneesh Arora sold 11,114 shares of the stock in a transaction on Monday, February 27th. The shares were sold at an average price of $21.50, for a total transaction of $238,951.00. Following the completion of the transaction, the chief operating officer now owns 535,940 shares in the company, valued at $11,522,710. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP D Scott Coward sold 1,543 shares of the stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $23.74, for a total transaction of $36,630.82. Following the transaction, the senior vice president now owns 55,478 shares of the company’s stock, valued at approximately $1,317,047.72. The disclosure for this sale can be found here. Insiders have sold 47,987 shares of company stock valued at $1,028,453 over the last ninety days. 5.60% of the stock is currently owned by corporate insiders.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.